ArticleStroke2017
Challenges in the Medical Management of Symptomatic Intracranial Stenosis in an Urban Setting.
Article in Stroke, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05907629 (Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Efficacy and safety of drug-eluting stents versus bare-metal stents in symptomatic intracranial and vertebral artery stenosis: a meta-analysis.Frontiers in neurology · 2024Pooled it
- Intracranial angioplasty with a self-expandable stent for intracranial atherosclerotic stenosis: Systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.JAMA neurology · 2022Trial
- Predictors of Early Infarct Recurrence in Patients With Symptomatic Intracranial Atherosclerotic Disease.Stroke · 2021Trial
- Impact of Intracranial Atherosclerosis and Cerebral Small Vessel Disease on Overt Vascular Events During Antithrombotic Therapy.European journal of neurology · 2026Observational
- Article
- Percutaneous Transluminal Angioplasty and Stenting for Symptomatic Intracranial Stenosis After SAMMPRIS: Patient Selection and Clinical Outcomes.Journal of clinical medicine · 2026Article
- Epidemiology, Pathophysiology, and Medical Management of Intracranial Atherosclerotic Disease.Journal of neuroendovascular therapy · 2026Review
- Stroke Mechanisms in Intracranial Atherosclerotic Disease: A Modified Classification System and Clinical Implications.Translational stroke research · 2025Article
- Stroke risk prediction in symptomatic anterior circulation ICAD: Analysis of regional QMRA flow from the MYRIAD study.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025Article
- A bibliometric and visualized analysis of interventional treatment for intracranial atherosclerotic stenosis (from 2004 to 2023).Neurosurgical review · 2025Review
- Article
- Self-expanding intracranial drug-eluting stent system in patients with symptomatic intracranial atherosclerotic stenosis: initial experience and midterm angiographic follow-up.Neuroradiology · 2024Article
- Alterations in metabolome and lipidome in patients with in-stent restenosis.CNS neuroscience & therapeutics · 2024Article
- Endovascular treatment of symptomatic severe intracranial atherosclerotic stenosis with a novel intracranial dedicated drug-eluting stent: a more effective treatment approach.Frontiers in neurology · 2024Article
- Endovascular re-canalization for symptomatic non-acute intracranial large artery occlusion: a single-center retrospective study.Quantitative imaging in medicine and surgery · 2023Article
- Angioplasty And stenting For symptomatic intracranial atherosclerotic disease: How I Do It.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2023Review
- Pitfalls of Randomized Controlled Trials in Stroke: How Can We Do Better?Stroke (Hoboken, N.J.) · 2023Article
- Elevated hs-CRP and Symptomatic Intracranial/Extracranial Artery Stenosis Predict Stroke Recurrence after Acute Ischemic Stroke or TIA.Journal of atherosclerosis and thrombosis · 2023Article
- Borderzone Infarcts and Recurrent Cerebrovascular Events in Symptomatic Intracranial Arterial Stenosis: A Systematic Review and Meta-Analysis.Journal of stroke · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeSince the SAMMPRIS trial (Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis), aggressive medical management (AMM), which includes dual antiplatelet therapy (DAPT) and high-dose statin (HDS) therapy, is recommended for patients with symptomatic intracranial atherosclerotic disease. However, limited data on the real-world application of this regimen exist. We hypothesized that recurrent stroke risk among patients treated with AMM is similar to the medical arm of the SAMMPRIS cohort.
methodsUsing a prospective registry, we identified all patients admitted between August 2012 and March 2015 with (1) confirmed ischemic stroke or transient ischemic attack; (2) independently adjudicated symptomatic intracranial atherosclerotic disease; and (3) follow-up at 30 days. We analyzed 30-day risk of recurrent ischemic stroke stratified by treatment: (1) AMM: DAPT plus HDS therapy, (2) HDS alone, and (3) DAPT alone. We also assessed 30-day risk among patients who met prespecified SAMMPRIS eligibility criteria.
resultsAmong 99 patients who met study criteria (51.5% male, 54.5% black, mean age 68.2±11.2 years), 49 (48.5%) patients were treated with AMM, 69 (69.7%) with DAPT, and 73 (73.7%) with HDS therapy. At 30 days, 20 (20.2%) patients had recurrent strokes in the territory of stenosis. Compared with the risk in the medical arm of SAMMPRIS (4.4%), the 30-day risk of recurrent stroke was 20.4% in AMM patients, 21.5% in HDS patients, 22.4% in DAPT patients, and 23.2% in SAMMPRIS-eligible patients (all
conclusionsRecurrent stroke risk within 30 days in patients with symptomatic intracranial atherosclerotic disease was higher than that observed in the medical arm of SAMMPRIS even in the subgroup receiving AMM. Replication of the SAMMPRIS findings requires further prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.